Alberto Sobrero

4PUBLICATIONS
29CO-AUTHORS
ChemotherapyPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jan 31, 2025
Endpoints for trials of adjuvant anticancer therapies.

Alessandro Pastorino, Alberto Sobrero, Paolo Bruzzi

|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.

Nadine J McCleary, William S Harmsen, Ellana Haakenstad

|May 17, 2021
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.

Arvind Dasari, Alberto Sobrero, James Yao

|Jan 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.

Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino

Pageof 1